Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections

Phase 3

Terminated

Conditions: Age-Related Macular Degeneration

Interventions: Biological: Aflibercept
Biological: Brolucizumab

First Posted Date: 2018-10-18

Last Posted Date: 2023-01-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 535

Registration Number: NCT03710564

Locations: 🇵🇷
Novartis Investigative Site, Arecibo, Puerto Rico

Managed Access Program to Provide Alpelisib for Patients With HR+ Advanced or Metastatic Breast Cancer

Conditions: HR+ Advanced or Metastatic Breast Cancer

First Posted Date: 2018-10-16

Last Posted Date: 2021-07-19

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT03706573

A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

Phase 3

Active, not recruiting

Conditions: Early Breast Cancer

Interventions: Other: Endocrine Therapy
Drug: Ribociclib

First Posted Date: 2018-10-10

Last Posted Date: 2024-11-14

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 5101

Registration Number: NCT03701334

Locations: 🇺🇸
University of Alabama at Birmingham-Kirklin Clinic, Birmingham, Alabama, United States
🇺🇸
Cancer Treatment Centers of America, Zion, Illinois, United States
🇺🇸
Comprehensive Blood and Cancer, Bakersfield, California, United States

and more 69 locations

Study to Determine Safety and Dose of NJH395 in Non-breast HER2+ Advanced Cancer

Phase 1

Completed

Conditions: NON-breast HER2+ Malignancies

Interventions: Drug: NJH395

First Posted Date: 2018-10-05

Last Posted Date: 2022-02-04

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 18

Registration Number: NCT03696771

Locations: 🇰🇷
Novartis Investigative Site, Seoul, Korea, Republic of
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects

Phase 1

Completed

Conditions: Non-alcoholic Fatty Liver Disease

Interventions: Drug: LJN452

First Posted Date: 2018-09-24

Last Posted Date: 2020-12-14

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 42

Registration Number: NCT03681457

Locations: 🇺🇸
Novartis Investigative Site, Knoxville, Tennessee, United States

Study of Efficacy of Fevipiprant in Patients With Nasal Polyposis and Asthma

Phase 3

Completed

Conditions: Nasal Polyps

Interventions: Drug: Fevipiprant 150 mg
Drug: Fevipiprant 450 mg
Drug: Placebo

First Posted Date: 2018-09-21

Last Posted Date: 2021-10-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 98

Registration Number: NCT03681093

Locations: 🇵🇱
Novartis Investigative Site, Zawadzkie, Poland

Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Ribociclib Placebo
Drug: Ribociclib
Drug: Letrozole
Drug: Goserelin

First Posted Date: 2018-09-14

Last Posted Date: 2025-05-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 327

Registration Number: NCT03671330

Locations: 🇨🇳
Novartis Investigative Site, Tianjin, China

Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis

Phase 3

Completed

Conditions: Moderate to Severe Chronic Plaque-type Psoriasis

Interventions: Drug: secukinumab high dose
Drug: secukinumab low dose

First Posted Date: 2018-09-12

Last Posted Date: 2025-05-16

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 84

Registration Number: NCT03668613

Locations: 🇺🇸
Texas Derm and Laser Specialists ., San Antonio, Texas, United States
🇺🇸
First OC Dermatology, Fountain Valley, California, United States
🇪🇸
Novartis Investigative Site, Valencia, Spain

and more 1 locations

Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients

Phase 2

Completed

Conditions: Kidney Transplant Rejection

Interventions: Drug: Tacrolimus - MMF - +/- corticosteroids
Biological: CFZ533 - MMF - CS

First Posted Date: 2018-09-10

Last Posted Date: 2022-06-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 418

Registration Number: NCT03663335

Locations: 🇬🇧
Novartis Investigative Site, Manchester, United Kingdom

Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients

Phase 2

Active, not recruiting

Conditions: Systemic Lupus Erythematosus (SLE)

Interventions: Drug: VAY736
Drug: CFZ533
Drug: VAY736 Placebo
Drug: CFZ533 Placebo

First Posted Date: 2018-09-04

Last Posted Date: 2024-12-27

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 107

Registration Number: NCT03656562

Locations: 🇹🇭
Novartis Investigative Site, Bangkok, Thailand

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy